Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers. / Schelde, Astrid Blicher; Petersen, Janne; Jensen, Thomas Bo; Gromov, Kirill; Overgaard, Søren; Olesen, Jonas Bjerring; Jimenez-Solem, Espen.
In: Basic & Clinical Pharmacology & Toxicology, Vol. 128, No. 3, 2021, p. 455-462.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers
AU - Schelde, Astrid Blicher
AU - Petersen, Janne
AU - Jensen, Thomas Bo
AU - Gromov, Kirill
AU - Overgaard, Søren
AU - Olesen, Jonas Bjerring
AU - Jimenez-Solem, Espen
PY - 2021
Y1 - 2021
N2 - The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population-based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2-78.6) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1-71.7) and 97.4% (95% CI: 97.1-97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2-83.5) and 99.4% (95% CI: 99.3-99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8-81.4) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7-85.1) and 100.0% (95% CI: 99.9-100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.
AB - The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population-based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2-78.6) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1-71.7) and 97.4% (95% CI: 97.1-97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2-83.5) and 99.4% (95% CI: 99.3-99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8-81.4) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7-85.1) and 100.0% (95% CI: 99.9-100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.
KW - clinical registers
KW - drug use
KW - electronic health record data
KW - pharmacoepidemiology
KW - validation study
KW - VENOUS THROMBOEMBOLISM
KW - REPLACEMENT
KW - THROMBOPROPHYLAXIS
KW - SYSTEM
U2 - 10.1111/bcpt.13518
DO - 10.1111/bcpt.13518
M3 - Journal article
C2 - 33053267
VL - 128
SP - 455
EP - 462
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 3
ER -
ID: 251685332